Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity

Journal of Cellular Biochemistry

Volumn 87, Issue 2, 2002, Pages 147-159

  Wang, Ying Jan ^a   Yu, Cheng Fei ^b   Chen, Li Ching ^c   Chen, Chien Ho ^b   Lin, Jen Kun ^d   Liang, Yu Chih ^e   Lin, Chien Huang ^b   Lin, Shyr Yi ^e,f   Chen, Chin Fa ^e   Ho, Yuan Soon ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cytochrome p450 (3A4); Ketoconazole; P53; Terfenadine

Indexed keywords

ANTIFUNGAL AGENT; CHLORPHENIRAMINE; CYTOCHROME P450 3A4; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; MEQUITAZINE; PROMETHAZINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; TERFENADINE;

ANTIFUNGAL ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL LINE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; COLORECTAL CANCER; DRUG INDUCED DISEASE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MONONUCLEAR CELL; MYCOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BACULOVIRIDAE; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 ENZYME SYSTEM; DNA FRAGMENTATION; DRUG INTERACTIONS; DRUG SYNERGISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INSECTS; KETOCONAZOLE; LIVER NEOPLASMS; MICROSOMES; RECOMBINANT PROTEINS; TERFENADINE; TUMOR CELLS, CULTURED;

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0036386412     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10282     Document Type: Article

References (70)

1. Back DJ, Stevenson P, Tjia JF. 1989. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin, and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 28:166-170.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Bates S, Vousden KH. 1996. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6:12-18.
4. Baune B, Flinois JP, Furlan V, Gimenez F, Taburet AM, Becquemont L, Farinotti R. 1999. Halofantrine metabolism in microsomes in man: Major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol 51:419-426.
5. Benson GD, Anderson PK, Combes B, Ishak KG. 1988. Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 33:240-246.
6. Bisschop MP, Merkus JM, Scheygrond H, Van Cutsem J, van de Kuy A. 1979. Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic. Eur J Obstet Gynecol Reprod Biol 9:253-259.
7. Boxenbaum H. 1999a. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: Determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharma Sci 2:47-52.
8. Boxenbaum H. 1999b. Human in vivo competitive inhibition of P450 substrates: Increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition. J Pharm Pharma Sci 2:89-91.
9. Brandon ML, Weiner M. 1980. Clinical investigation of terfenadine, a non-sedating antihistamine. Ann Allergy 44:71-75.
10. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. 1990. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:1973-1977.
11. Chen RJ, Lee WS, Liang YC, Lin JK, Wang YJ, Lin CH, Hsieh JY, Chaing CC, Ho YS. 2000. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 169:132-141.
12. Darlington GJ, Kelly JH, Buffone GJ. 1987. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell Dev Biol 23:349-354.
13. Diaz-Trelles R, Solana-Lopez A, Fernandez-Gonzalez JR, Novelli A, Fernandez-Sanchez MT. 1999. Terfenadine induces toxicity in cultured cerebellar neurons: A role for glutamate receptors. Amino Acids 16:59-70.
14. Diaz-Trelles R, Novelli A, Vega JA, Marini A, Fernandez-Sanchez MT. 2000. Antihistamine terfenadine potentiates NMDA receptor-mediated calcium influx, oxygen radical formation, and neuronal death. Brain Res 880: 17-27.
15. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
16. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. 1996. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 277:991-998.
17. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. 1997. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
18. Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE. 2000. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm Res 17:299-305.
19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
20. Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM. 1999. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer 81:622-630.
21. Gupta A, Sexton RC, Rudney H. 1986. Modulation of regulatory oxysterol formation and low density lipoprotein suppression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity by ketoconazole. A role for cytochrome P-450 in the regulation of HMG-CoA reductase in rat intestinal epithelial cells. J Biol Chem 261:8348-8356.
22. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. 1998. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472.
23. Herman BD, Fleishaker JC, Brown MT. 1999. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 66:374-379.
24. Hey JA, del Prado M, Kreutner W, Egan RW. 1996a. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittelforschung 46:159-163.
25. Hey JA, del Prado M, Sherwood J, Kreutner W, Egan RW. 1996b. The guinea pig model for assessing cardiotoxic proclivities of second generation antihistamines. Arzneimittelforschung 46:834-837.
26. Ho YS, Wang YJ, Lin JK. 1996. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog 16:20-31.
27. Ho YS, Lee HM, Mou TC, Wang YJ, Lin JK. 1997. Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. Mol Carcinog 19:101-113.
28. Ho YS, Tsai PW, Yu CF, Liu HL, Chen RJ, Lin JK. 1998. Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 153:39-47.
29. Ho YS, Lee HM, Chang CR, Lin JK. 1999a. Induction of Bax protein and degradation of lamin A during p53-dependent apoptosis induced by chemotherapeutic agents in human cancer cell lines. Biochem Pharmacol 57:143-154.
30. 2+ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. Mol Carcinog 26:201-211.
31. Ho YS, Duh JS, Jeng JH, Wang YJ, Liang YC, Lin CH, Tseng CJ, Yu CF, Chen RJ, Lin JK. 2001. Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells. Int J Cancer 91:393-401.
32. Holen E, Elsayed S, Nyfors A. 1995. The effect of H1 receptor antagonists on peripheral blood mononuclear cells, adenoid cells, and primary cell lines. Apmis 103: 98-106.
33. Jiang MC, Yang-Yen HF, Lin JK, Yen JJ. 1996. Differential regulation of p53, c-Myc, Bcl-2, and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Oncogene 13: 609-616.
34. Jurima-Romet M, Crawford K, Cyr T, Inaba T. 1994. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
35. Kaliner MA, Check WA. 1988. Non-sedating antihistamines. Allergy Proc 9:649-663.
36. Khoo SM, Porter JH, Edwards GA, Charman WN. 1998. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci 87:1538-1541.
37. King KL, Cidlowski JA. 1995. Cell cycle and apoptosis: Common pathways to life and death. J Cell Biochem 58: 175-180.
38. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC. 1996. Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 12:187-192.
39. Knowles BB, Howe CC, Aden DP. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499.
40. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, Chiba K. 2000. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6:3297-3303.
41. Lake-Bakaar G, Scheuer PJ, Sherlock S. 1987. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J Clin Res Ed 294:419-422.
42. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. 1984. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86:503-513.
43. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. 1995. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
44. 2+ Channel current in rat ventricular myocytes by terfenadine. Circ Res 81:202-210.
45. Lu Y, Wang Z. 1999. Terfenadine block of sodium current in canine atrial myocytes. J Cardiovasc Pharmacol 33:507-513.
46. Meredith CG, Maldonado AL, Speeg KV. 1985. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Dispos 13:156-162.
47. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
48. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
49. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR, Jr. 1990. Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
50. Mosca P, Bonazzi P, Novelli G, Jezequel AM, Orlandi F. 1985. In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br J Exp Pathol 66:737-742.
51. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T. 1999. Azelastine N-demethylation by cytochrome P450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381-1391.
52. Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, Kamataki T. 1996. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 6:449-457.
53. Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, Shimizu T, Kamataki T. 1998. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 284:437-442.
54. Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
55. Niewolik D, Vojtesek B, Kovarik J. 1995. p53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881-890.
56. Nnane IP, Kato K, Liu Y, Lu Q, Wang X, Ling YZ, Brodie A. 1998. Effects of some novel inhibitors of C17,20-lyase, and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Cancer Res 58:3826-3832.
57. Paine MF, Schmiedlin-Ren P, Watkins PB. 1999. Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 27:360-364.
58. Parker RS, Sontag TJ, Swanson JE. 2000. Cytochrome P4503A-dependent metabolism of tocopherols and inhibition by sesamin. Biochem Biophys Res Commun 277: 531-534.
59. Rafferty P, Holgate ST. 1987. Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways. Am Rev Respir Dis 135:181-184.
60. Roberts DJ, Llenas J. 1996. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig. Arzneimittelforschung 46:832-833.
61. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, Estabrook RW. 1995. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
62. Semple TU, Quinn LA, Woods LK, Moore GE. 1978. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res 38:1345-1355.
63. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. 1995. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-809.
64. Trachtenberg J, Pont A. 1984. Ketoconazole therapy for advanced prostate cancer. Lancet 2:433-435.
65. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. 1999. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
66. Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. 1998. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 50: 265-274.
67. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. 1994. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
68. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. 1996. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16:104-112.
69. Williams G. 1984. Ketoconazole for prostate cancer [Letter]. Lancet 2:696.
70. Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL. 1995. Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther 58:210-220.